Phase 1 Study (NCT04429542): Ficerafusp alfa with/without pembrolizumab in advanced solid tumors. https://t.co/edPjg4G7jp

Thinking about cancer recurrence can be scary! The NavDx® test by Naveris® can help take some of the fear and dread out of cancer surveillance for HPV-driven oropharyngeal and anal squamous cell cancer patients. Learn more today! https://t.co/bWROp3q51x #Naveris #NavDx #oncology

.@DanaFarber’s @HeadNeckMD discusses the results of “A Phase I Trial of the MYB RNA Degrader REM-422 in Patients with Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (ACC),” which he is presenting today in the Clinical Trials Plenary Session at the AACR-NCI-EORTC

Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M ACC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Full PR here: https://t.co/OKF9oEgCld

Are you or a loved one living with head and neck cancer? The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients.  @BicaraTx    https://t.co/re6l1gjdcF   #ClinicalTrial #HeadAndNeckCancer #CancerResearch

This #ESMO25, we will be sharing our new clinical data from our farnesyl transferase inhibitor (FTI) programs. The results highlight our progress in advancing these programs to potentially treat solid tumors with limited treatment options. Full details: https://t.co/n4bgTypgeZ

We’re pleased to share that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for ficerafusp alfa in combination with pembrolizumab for the treatment of patients with 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell

In a Q&A, Glenn J. Hanna, MD (@HeadNeckMD) discussed: ✅ The ongoing development of micvotabart pelidotin 📊 The importance of biomarker-driven treatment approaches for HNSCC 🌟 And more! @DanaFarberNews Read his insights:

Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report, ranked as #3 in the nation and the only one top ranked in New England for 2025-26. Learn more: https://t.co/JOZgF0nBf7

⏰🚨👏ReACT1.0 #ASCO25 @HeadNeckMD @jdschoenfeld1 @MargalitMd @DrHaddadRobert 🌟 Ph2, stage I-III HPV+ OPC 🌟54-66Gy gross dz based on risk/DNA clearance 🌟30-54Gy elective 🌟~60%>95% clearance at wk 4-5 🌟2yr PFS 90% - 5 events (1 death): 3LRR, 4DM

Today at #ASCO25: @HeadNeckMD of @DanaFarber presents phase 2 data suggesting circulating HPV DNA can be a biomarker before & during treatment for HPV-positive oropharyngeal cancer to guide treatment intensity w/o compromising PFS survival in higher-risk pts.

Dr. @HeadNeckMD explains how adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in patients with head and neck cancers. Learn more: https://t.co/lR4fs22wpB #ASCO25 #hncsm

💊 Breaking science, straight from #ASCO25: #Nivolumab ➕standard chemoradiotherapy slashed risk for recurrence or death by 2⃣4⃣% in patients with resected, locally advanced #HNSCC 💡 “Tremendous” results, noted Dr. Glenn J. Hanna @HeadNeckMD @DanaFarber https://t.co/5QUhgPlDsR

Early morning press briefing at #asco25 @ASCO

🎙️ Throwback Thursday: Immunobuddies Podcast Highlight from November 2023! 🎇 🧡 Managing Immunotherapy in Organ Transplant Patients 🧡 📍 Featuring: Dr. Glenn Hanna Associate Professor, Harvard Medical School Dana-Farber Cancer Institute, Boston 🩺 A 2-part deep dive into: ✅

‼️Our paper on clinical trials for patients with salivary gland cancers is now published! 🙌80% funded by Academia. Need to attract pharma interest! 🟠50% unicenter, 80% single country. Need for ⬆️ collaboration! 🟠55% enrolled any type of histologies without stratification

At @AACR @HeadNeckMD of @DanaFarber says phase II findings are relatively encouraging for pts with advanced salivary tumors, a population with high unmet clinical need with no current approved therapies. The study looked at elraglusib + chemotherapy.

Reminder: Actuate will present data on its lead investigational drug, elraglusib, in advanced salivary gland carcinoma during a poster session at the @AACR Annual Meeting 2025, tomorrow, April 29th at 2 PM CT. For more details, visit: https://t.co/HiEtCNtiSC $ACTU #AACR25

Encouraging new data at #AACR25 on micvotabart pelidotin (next-generation ADC that targets EDB+FN). Extracellular cleavage ADCs seem to have potential. Focusing on EDB+FN overexpressed in the TME may elicit sustained anti-tumor response. @PyxisOncology

Charles Kung presenting REM-422, a first-in-class, orally available small molecule degrader of MYB mRNA at #AACR today. REM-422 induces tumor regressions in MYB-dysregulated preclinical models at well tolerated doses & is in two Phase 1 clinical trials. https://t.co/4kKinsm7vF